Penn Medicine Provider
Gynecologic Oncology
Robert L. Giuntoli, II, MD
5.0
(720)
Accepting new patients
Sees patients age 12 and up
Abramson Cancer Center West Chester
View 1 additional location
Make an appointmentCall 800-789-7366

About me

  • Medical Director of Surgical Oncology at Penn Medicine Chester County Hospital
  • Director of Gynecologic Oncology Penn Medicine Chester County Hospital
  • Professor of Clinical Obstetrics and Gynecology

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Duke University Medical Center
  • Fellowship: Women & Infant's Hospital of Rhode Island
  • Fellowship: Mayo Clinic

What my patients think about me

Average Rating
5.0

720 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

July 2025
5.0
5.0
i trust the doctor.
July 2025
5.0
5.0
i liked him
July 2025
5.0
5.0
compassionate
July 2025
5.0
5.0
dr giuntoli has been consistent in discussing treatment options from a surgical perspective

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Giuntoli is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Caruso G, Ainio C, Fumagalli D, Reynolds EA, Nasioudis D, Mc Gree ME, Fought AJ, Giuntoli RL, Mariani A, Cliby WA. Textbook oncologic outcome in endometrial cancer surgery: A quality measure to improve survival and address disparities , Gynecol Oncol, 200: 2025,33-43

Tubridy E, Gysler S, Latif NA, Ko EM, Giuntoli RL 2nd, Kim SH, Nasioudis D. Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma , Int J Gynecol Cancer: 2025

Mulugeta-Gordon L, Gysler S, Latif NA, Ko EM, Giuntoli RL 2nd, Kim SH, Nasioudis D. Quality of adjuvant radiation therapy and impact on the survival of patients with lymph node-positive squamous cell carcinoma of the vulva , Int J Gynecol Cancer: 2025

Caruso G, Kumar A, Langstraat CL, McGree ME, Fought AJ, Harrington S, Nasioudis D, Aletti GD, Colombo N, Giuntoli RL, Cliby W. Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer , Gynecol Oncol: 2025

Nasioudis D, Gysler S, Latif NA, Giuntoli RL 2nd, Kim SH, Ko EM. Incidence of lymph node metastases in patients with apparent early-stage endometrioid ovarian carcinoma , Int J Gynecol Cancer: 2025

Nasioudis D, Labban N, Gysler S, Ko EM, Giuntoli RL 2nd, Kim SH, Latif NA Outcomes of Radical Hysterectomy for Early-Stage Cervical Carcinoma, with or without Prior Cervical Excision Procedure. , Cancers (Basel), 16(11):2051: 2024

Nasioudis D, Gysler S, Latif NA, Giuntoli RL 2nd, Kim SH, Ko EM Role of systematic lymphadenectomy at the time of interval debulking surgery for patients with advanced-stage epithelial ovarian carcinoma who achieved complete gross resection. , Int J Gynecol Cancer, 34(7):969-974: 2024

Nasioudis D, Gysler S, Latif N, Cory L, Giuntoli RL 2nd, Kim SH, Simpkins F, Martin L, Ko EM Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions. , Gynecol Oncol, 180:1-5: 2024

Nasioudis D, Wang X, Dhillon G, Latif N, Ko EM, Giuntoli RL 2nd, Gershenson D, Fader A, Carey M, Simpkins F Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. , Int J Gynecol Cancer: 2023,33(12):1906-1912

Nasioudis D, Arevalo O, Gysler S, Ko EM, Cory L, Kim SH, Giuntoli RL 2nd, Latif NA Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma. , Int J Gynecol Cancer, ijgc-2023-004805: 2023